Read + Share
Wu J, Song Y, Chen X, Lin T, et al. Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended
follow-up of the multicenter, single-arm, phase 2 study. Int J Cancer 2021 Oct 21. doi: 10.1002/ijc.33852.
PMID: 34674396
|
 |
|
Wu J, Song Y, Chen X, Lin T, et al. Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended
follow-up of the multicenter, single-arm, phase 2 study. Int J Cancer 2021 Oct 21. doi: 10.1002/ijc.33852.
PMID: 34674396
|
|
|
|